At a glance
ClinicalIndex Comparison RecordN/ACompleted· 30 enrolled
Drug / intervention
The Neovasc Reducer™ Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study Testing the Feasibility and Efficacy of Coronary Sinus Narrowing in Patients With Coronary Microvascular Dysfunction
In Brief
A clinical study evaluating The Neovasc Reducer™ System for Coronary Microvascular Dysfunction. Completed, enrolled 30 participants across 1 site.
Detailed Summary
This study is being done to evaluate the role of a novel implantable device, called The Neovasc Reducer™ System, in improving microvascular function, symptoms and quality of life in symptomatic patients with coronary microvascular dysfunction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Microvascular Dysfunction
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartJun 2021
Primary CompletionJul 2023
TodayJul 2026
First PostedAug 21, 2020
Enrollment StartJun 28, 2021
Primary CompletionJul 28, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.9 years ago
Interventions
The Neovasc Reducer™ Systemdevice
A stainless-steel mesh pre-mounted on a customized hourglass shaped balloon catheter, is designed to create a focal narrowing in the lumen of the CS to generate a pressure gradient across it.